Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-25-296
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $650,000
Opportunity facts
- Assistance listings
-
- 93.350 National Center for Advancing Translational Sciences
- 93.313 NIH Office of Research on Women's Health
- 93.855 Allergy and Infectious Diseases Research
- 93.172 Human Genome Research
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- 93.121 Oral Diseases and Disorders Research
- 93.865 Child Health and Human Development Extramural Research
- 93.307 Minority Health and Health Disparities Research
- 93.859 Biomedical Research and Research Training
- Funding instrument
- Cooperative Agreement
- Categories
-
- Health
- Income Security and Social Services
- Eligible applicants
-
- Higher Education Inst. (Public)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting investigator-initiated applications for the Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) through a cooperative agreement mechanism, with applications due October 19, 2027. Eligible applicants are limited to public higher education institutions; non-domestic entities and non-domestic components of U.S. organizations are not eligible.
The program aims to accelerate translational research by supporting collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium. Applicants must develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase research impact across diseases, transform the field of translational science, and bring treatments to broader populations more quickly. Clinical trials are optional under this opportunity.
The award operates across multiple NIH research programs including Women's Health (93.313), Arthritis Research (93.846), Child Health (93.865), Oral Health (93.121), Minority Health (93.307), Infectious Diseases (93.855), Biomedical Research (93.859), Human Genome Research (93.172), and Translational Sciences (93.350). Applications undergo peer review for scientific and technical merit by an initial review group, followed by secondary review by the relevant national advisory council. Grantees must retain financial and programmatic records for three years from the date of annual Financial Status Report submission. Award recipients are subject to audit by HHS and other federal officials.
Synopsis
The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.
Eligibility
Other Eligible Applicants include the following: See NOFO for further eligibility criteria. Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-296-Full-Announcement.html | HTML file | |
| PKG00289592.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity